Research ArticleCancer

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

See allHide authors and affiliations

Science Translational Medicine  07 Aug 2019:
Vol. 11, Issue 504, eaax7392
DOI: 10.1126/scitranslmed.aax7392

Early detection, no time travel needed

Analysis of tumor DNA shed into a patient’s circulation can provide a noninvasive means of detecting the presence of a tumor and analyzing its DNA for targetable mutations. Unfortunately, it can be difficult to detect small amounts of tumor DNA in the blood, especially in patients who have already undergone initial chemotherapy treatment. To address this problem, McDonald et al. developed a method of targeted digital sequencing (TARDIS), which is customized for each patient but can then be used to monitor the patient over time for and allow early detection of tumor recurrence.

View Full Text